Yuhan Corporation Stock Outlook 2026: A Value Pharma Re-Rated by a J&J Oncology Royalty
Yuhan Corporation (KRX: 000100) 2026 stock analysis: a stable base of prescription, OTC, consumer-health and API businesses meets a transformational catalyst — lazertinib (Lazcluze/Leclaza), out-licensed to Johnson & Johnson, generating milestone and royalty income in EGFR lung cancer. Bull case, single-asset risk, governance, and what global investors should watch.
Yuhan 000100 Korea Stocks